Claims for Patent: 9,410,971

Summary for Patent: 9,410,971

Title:	Devices, systems and methods for evaluation of hemostasis
Abstract:	Provided are devices, systems and methods for evaluation of hemostasis. Also provided are sound focusing assemblies.
Inventor(s):	Viola; Francesco (Charlottesville, VA), Walker; William F. (Charlottesville, VA), Browne; Gregory V. (Victoria, CA), Magyar; Robert S. (Victoria, CA), Hansen; Bjarne (Victoria, CA), Denny; Christopher G. (Victoria, CA)
Assignee:	HemoSonics LLC (Charlottesville, VA)
Application Number:	15/003,325
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,410,971
Patent Claims:	1. A device for evaluation of hemostasis, comprising: a plurality of test chambers each configured to receive blood of a test sample, each test chamber comprising a reagent or combination of reagents, wherein each chamber is configured to be interrogated to determine a hemostatic parameter of the blood received therein; a first chamber of the plurality comprising a first reagent or a first combination of reagents that interact with the blood received therein, wherein the first reagent, or a reagent included in the first combination of reagents, is an activator of coagulation; a second chamber of the plurality comprising a second combination of reagents that interact with blood of the test sample received therein, the second combination including an activator of coagulation and one or both of abciximab and cytochalasin D; and an interrogation device that measures at least one viscoelastic property of the test sample. 2. The device of claim 1, further comprising: a third chamber comprising a third reagent or combination of reagents that interact with blood of the test sample received therein; a fourth chamber comprising a fourth reagent or combination of reagents that interact with blood of the test sample received therein; and wherein the third and fourth chambers are configured to be interrogated to determine a hemostatic parameter of the test sample. 3. The device of claim 1, wherein the interrogation device is configured to use acoustic radiation force. 4. The device of claim 1, wherein the interrogation device is configured to transmit sound into one or more test chamber. 5. The device of claim 1, wherein the first reagent and the second combination of reagents are lyophilized prior to interacting with the test samples. 6. The device of claim 1, wherein each test chamber of the plurality of test chambers is at least partially defined by a housing. 7. The device of claim 6, wherein the device is configured for use with a single test sample. 8. The device of claim 7, further comprising a fluid pathway having an inlet for receiving a test sample, wherein the fluid pathway is in communication with at least one test chamber to deliver the test sample, or a portion thereof, to one or more of the test chambers. 9. The device of claim 8, wherein the housing defines at least a portion of the fluid pathway, and wherein at least a portion of the housing is thermally conductive. 10. The device of claim 9, wherein the thermally conductive portion of the housing defines at least a portion of the fluid pathway. 11. The device of claim 10, wherein the thermally conductive portion comprises a thermally conductive polymer. 12. The device of claim 8, wherein the fluid pathway further comprises a channel in communication with a least one test chamber, and wherein sample delivered from the channel into the test chamber results in mixing of at least a portion of the sample and the reagent within the test chamber. 13. The device of claim 12, wherein the fluid pathway further comprises a channel that opens into at least one test chamber on the side and at a tangent to the test chamber. 14. The device of claim 7, wherein one or more test chamber of the plurality of test chambers further comprises a magnetic stirring structure. 15. The device of claim 1, wherein the second chamber comprises a combination of reagents that includes a reagent comprised by the first chamber. 16. The device of claim 1, wherein the first chamber comprises a first combination of reagents including one or more of reagents selected from the group consisting of kaolin, celite, glass, thrombin, ellagic acid, and tissue factor, and wherein the second chamber comprises the second combination of reagents including one or more reagents selected from the group consisting of kaolin, celite, glass, thrombin, ellagic acid, and tissue factor. 17. A system for evaluation of hemostasis comprising: a plurality of test chambers each configured to receive blood of a test sample, each test chamber comprising a reagent or combination of reagents; wherein a first chamber of the plurality comprises an activator of coagulation that interact with the blood received therein; wherein a second chamber of the plurality comprises an activator of coagulation and one or both of abciximab and cytochalasin D that interact with blood of the test sample received therein the combination including an activator of coagulation and; wherein the first chamber is configured to be interrogated with ultrasound for a hemostatic parameter of the blood received therein to be determined; wherein the second chamber is configured to be interrogated with ultrasound for a hemostatic parameter of the blood received therein to be determined; a transducer for transmitting ultrasound into one or more test chamber and for receiving reflected ultrasound from the chamber and the sample therein; and at least one processor in communication with the transducer, the processor being configured to determine the hemostatic parameters from signals transmitted to the processor from the transducer. 18. The system of claim 17, wherein the hemostasis parameters are selected from the group consisting of TC1, TC2, clot stiffness, clot formation rate (CFR), TL1, TL2, baseline viscosity, and post lysis viscosity. 19. The system of claim 17, wherein the processor is further configured to determine a coagulation factors index. 20. The system of claim 17, wherein the processor is further configured to determine at least one parameter selected from the group consisting of an intrinsic pathway coagulation factors index, an extrinsic pathway coagulation factors index, a platelets index, a fibrinogen index, and a fibrinolysis index.

Details for Patent 9,410,971

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REOPRO	abciximab	Injection	103575	12/22/1994		2031-02-15